Answers are grounded in this paper and cite their sources.
This review summarizes how sophisticated imaging, immunohistochemical testing, and molecular-profiling tools are changing the approach to cancer of unknown primary site. Increasingly, treatment decisions are personalized on the basis of the mutational status of a patient's tumor.
No takes yet. Share an insight, caveat, or question.
Varadhachary et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: